Collecting Duct Carcinoma and Renal Medullary Carcinoma

The Kidney ◽  
2016 ◽  
pp. 109-123
Author(s):  
Jamie Koo ◽  
Christopher P. Filson ◽  
Jiaoti Huang ◽  
Allan J. Pantuck
Keyword(s):  
Collecting Duct ◽  
Medullary Carcinoma ◽  
Duct Carcinoma ◽  
Collecting Duct Carcinoma ◽  
Renal Medullary Carcinoma

scholarly journals Collecting Duct Carcinoma Versus Renal Medullary Carcinoma

2014 ◽  
Vol 38 (7) ◽  
pp. 871-874 ◽  
Author(s):  
Mahul B. Amin ◽  
Steven C. Smith ◽  
Abbas Agaimy ◽  
Pedram Argani ◽  
Eva Marie Compérat ◽  
...  
Keyword(s):  
Collecting Duct ◽  
Medullary Carcinoma ◽  
Duct Carcinoma ◽  
Collecting Duct Carcinoma ◽  
Renal Medullary Carcinoma

scholarly journals Renal Medullary Carcinoma

2019 ◽  
Vol 143 (12) ◽  
pp. 1556-1561 ◽  
Author(s):  
Alexis Elliott ◽  
Evelyn Bruner
Keyword(s):  
Sickle Cell ◽  
Sickle Cell Trait ◽  
Collecting Duct ◽  
Malignant Neoplasm ◽  
Young Male ◽  
Medullary Carcinoma ◽  
Malignant Rhabdoid Tumor ◽  
Duct Carcinoma ◽  
Renal Medullary Carcinoma ◽  
Time Of Presentation

Renal medullary carcinoma, also referred to as the seventh sickle cell nephropathy, typically affects young African Americans with sickle cell trait, or, less frequently, patients with sickle cell disease. The existence of renal medullary carcinoma without a concomitant hemoglobinopathy is a topic of controversy. The typical patient is a young male of African or Mediterranean descent, with hematuria and/or flank pain. Most patients have metastatic disease at the time of presentation. The tumor is characteristically a poorly circumscribed mass in the medullary region, commonly showing variable amounts of hemorrhage and necrosis. Microscopically, a characteristic reticular or cribriform pattern with a striking desmoplastic stromal response and a robust mixed inflammatory infiltrate is observed. Collecting duct carcinoma, malignant rhabdoid tumor, urothelial carcinoma, and other subtypes of renal cell carcinoma are in the differential diagnosis. Because of the advanced stage of disease at presentation and the aggressive nature of this malignant neoplasm, survival is poor even with chemotherapy; however, isolated reports of prolonged survival have been documented.

Comprehensive profiling of renal medullary and collecting duct carcinomas.

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 572-572
Author(s):  
Thai Huu Ho ◽  
Jeffrey Swensen ◽  
Anatole Ghazalpour ◽  
Ondrej Hes ◽  
Melissa L. Stanton ◽  
...  
Keyword(s):  
Sickle Cell ◽  
Sickle Cell Trait ◽  
Collecting Duct ◽  
Tumor Infiltrating Lymphocytes ◽  
Medullary Carcinoma ◽  
Duct Carcinoma ◽  
Collecting Duct Carcinoma ◽  
Patients Âgés ◽  
Human Pathology ◽  
Alk Protein

572 Background: Renal medullary carcinoma (RMC) is an aggressive malignancy affecting predominantly young African Americans with sickle cell trait (SCT) or disease (SCD), while a pathologically similar collecting duct carcinoma (CDC) affects patients without sickle cell trait. Clinical responses to chemotherapy and IL-2 in RMC/CDC are poor and novel therapies are needed. Methods: 9 patients with RMC (ages 13-58 y. o., all male) and 15 patients (ages 26-74 y. o., M:F = 13:2) with collecting duct carcinoma (CDC) were studied. Expression of PD-L1 was evaluated with 2 monoclonal antibodies (SP142 and SP263) and tumor infiltrating lymphocytes (TIL) were evaluated for PD1 expression (MRQ-22 antibody) using immunohistochemistry (IHC). Additional studies included ALK protein expression (D5F3 antibody), gene translocation (break apart FISH), next generation sequencing (NGS), and microsatellite instability (MSI). Results: Cancer cell PD-L1 expression above the threshold ( ≥ 2+, ≥ 5%) was seen in 7/9 RMC and 5/13 CDC cases. Concordance between 2 PD-L1 antibodies was 94.4%. PD-1+ TIL were absent in 6/18 cases and variably present in 12/18 cases (from 1 to > 15 TIL/40x power field). No MSI was detected in any of the cases tested (0/6). No case expressed ALK protein, but one case of CDC showed ALK gene re-arrangement. Mutations were identified in SMARCB1, FH, TP53 (3x), ATM, BRCA2, CHEK2 (2x), NF2 (3x), SETD2, and CDKN2A. No mutations in VHL or KDR were detected. One patient with RMC (and SCT) achieved complete clinical remission after treatment with bevacizumab plus paclitaxel. Conclusions: RMC and CDC strongly express PD-L1 in the majority of cases (12/22), suggesting that these patients may benefit from targeting the PD-L1/PD1 interaction. The absence of MSI in these cancers indicates a different mechanism of PD-L1 upregulation from colorectal carcinomas. Consistent with our previous study that showed frequent activation of (pseudo)hypoxia-induced pathways in RMCs (Human Pathology 2011;42:1979), we describe a case of RMC successfully treated with anti-VEGF therapy.

A case of collecting duct carcinoma (Bellini duct carcinoma) infiltrating diffusely into the entire right kidney

Choonpa Igaku ◽  
2013 ◽  
Vol 40 (2) ◽  
pp. 183-189
Author(s):  
Naoko SHIMAMORI ◽  
Tomonori KISHINO ◽  
Hiroaki OHNISHI ◽  
Mitsuhiro TAMBO ◽  
Yuichi TERADO ◽  
...  
Keyword(s):  
Collecting Duct ◽  
Duct Carcinoma ◽  
Collecting Duct Carcinoma ◽  
Bellini Duct Carcinoma

The Histological and Immunohistochemical Appearance of a Very Rare Entity – Bellini’s Collecting Duct Carcinoma

2020 ◽  
Vol 13 (62) (1) ◽  
pp. 45-52
Author(s):  
Andreea Catalina Tinca ◽  
◽  
Mihaela Cornelia Sincu ◽  
Daniel Hodade Porav ◽  
◽  
...  
Keyword(s):  
Collecting Duct ◽  
Rare Entity ◽  
Duct Carcinoma ◽  
Collecting Duct Carcinoma

Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery

Urology ◽  
2001 ◽  
Vol 58 (6) ◽  
pp. 1058 ◽  
Author(s):  
Jared A Gollob ◽  
Melissa P Upton ◽  
William C DeWolf ◽  
Michael B Atkins
Keyword(s):  
Collecting Duct ◽  
Duct Carcinoma ◽  
Collecting Duct Carcinoma

scholarly journals Collecting Duct Carcinoma Presenting Uncommon Metastatic Features

2012 ◽  
Vol 98 (5) ◽  
pp. e135-e138
Author(s):  
Ke Cheng ◽  
Ye Chen ◽  
Feng Zhao ◽  
Feng Gao ◽  
Hai-Tao Men ◽  
...  
Keyword(s):  
Collecting Duct ◽  
Duct Carcinoma ◽  
Collecting Duct Carcinoma
Sign in / Sign up

Export Citation Format

Share Document